Incorporated – SBS Internet Solutions http://www.sbs-internetsolutions.com/ Mon, 21 Nov 2022 10:54:32 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 http://www.sbs-internetsolutions.com/wp-content/uploads/2021/06/cropped-icon-32x32.png Incorporated – SBS Internet Solutions http://www.sbs-internetsolutions.com/ 32 32 James Kamsickas is the chairman of Dana Incorporated (NYSE:DAN) and they just sold 53% of their stock http://www.sbs-internetsolutions.com/james-kamsickas-is-the-chairman-of-dana-incorporated-nysedan-and-they-just-sold-53-of-their-stock/ Mon, 21 Nov 2022 10:16:48 +0000 http://www.sbs-internetsolutions.com/james-kamsickas-is-the-chairman-of-dana-incorporated-nysedan-and-they-just-sold-53-of-their-stock/ Some Dana Incorporated (NYSE:DAN) Shareholders might be a little concerned that Chairman James Kamsickas recently sold $7.1 million worth of stock at $17.78 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 53% of their entire stake. Check opportunities and risks within the US automotive components industry. […]]]>

Some Dana Incorporated (NYSE:DAN) Shareholders might be a little concerned that Chairman James Kamsickas recently sold $7.1 million worth of stock at $17.78 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 53% of their entire stake.

Check opportunities and risks within the US automotive components industry.

The last 12 months of insider trading at Dana

In fact, the recent sale by James Kamsickas was the largest sale of Dana stock by an insider in the past twelve months, according to our records. This means that even when the stock price was below the current price of US$18.24, an insider wanted to cash out some shares. We generally consider it negative if insiders sold, especially if they did below the current price, as this implies that they considered a lower price to be reasonable. While insider selling is not a positive sign, we can’t be sure if it means insiders believe the stock is fully priced, so it’s only a weak sign. Note that this sale involved 53% of James Kamsickas’ stake.

You can see a visual representation of insider trading (by companies and individuals) over the past 12 months, below. If you want to know exactly who sold, how much and when, just click on the chart below!

NYSE:DAN Insider Trading Volume November 21, 2022

For those who like to find winning investments this free list of growing companies with recent insider buying, might be just the ticket.

Does Dana boast of being a high initiate level owner?

Examining the total insider holdings in a company can help you know if they are well aligned with common shareholders. We generally like to see fairly high levels of insider ownership. It appears that Dana insiders own 0.9% of the company, worth around $22 million. While this is a high but not exceptional level of insider ownership, it suffices to indicate some alignment between management and small shareholders.

So what do Dana insider trades indicate?

An insider hasn’t bought Dana stock in the past three months, but there have been some sales. Zooming out, the longer term image doesn’t give us much comfort. Insiders hold shares, but we remain quite cautious, given the history of sales. We are in no rush to buy! While we like to know what’s going on with insider ownership and trading, we also make sure to consider the risks a stock faces before making an investment decision. Know that Dana shows 3 warning signs in our investment analysisand 2 of them are significant…

Sure Dana may not be the best stock to buy. So you might want to see this free set of high quality companies.

For the purposes of this article, insiders are persons who report their transactions to the relevant regulatory body. We currently record open market transactions and private dispositions, but not derivative transactions.

Valuation is complex, but we help make it simple.

Find out if Dana is potentially overvalued or undervalued by viewing our full analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.

See the free analysis

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

]]>
Integration of pediatric diets in the treatment of ALL http://www.sbs-internetsolutions.com/integration-of-pediatric-diets-in-the-treatment-of-all/ Fri, 18 Nov 2022 11:06:33 +0000 http://www.sbs-internetsolutions.com/integration-of-pediatric-diets-in-the-treatment-of-all/ Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia at the National Comprehensive Cancer Network’s 2022 Annual Meeting: Malignant Hematologies. Mark R. Litzow, MD, Chairman, Professor of Medicine, Division of Hematology, Mayo Clinic, discusses the presentation he gave on initial treatment options for patients with […]]]>

Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia at the National Comprehensive Cancer Network’s 2022 Annual Meeting: Malignant Hematologies.

Mark R. Litzow, MD, Chairman, Professor of Medicine, Division of Hematology, Mayo Clinic, discusses the presentation he gave on initial treatment options for patients with acute lymphoblastic leukemia (ALL) at the National Comprehensive Cancer Network Annual Meeting 2022: Malignant Hematologies.

After years of little to no new developments in the ALL space, experts have found that young adults up to age 40 with ALL can tolerate pediatric treatment regimens. By providing patients with additional doses of these agents, better survival outcomes have been observed.

As young adults and pediatric patients are able to tolerate these intensive regimens, they are now beginning to be incorporated into the treatment of this patient population.

Transcription:

0:08 | I have focused in my talk on initial treatment options for patients with acute lymphoblastic leukemia and risk stratification. Some of the new developments in ALL, and there have been many that have been very exciting for us after many years of stagnation where we didn’t have many new treatments, one of the important things we learned is that in young adults with ALL, they can tolerate treatment programs that have been used in children, thus pediatric diets. These diets contain more drugs like vincristine, asparaginase and corticosteroids.

0:50 | It appears that extra doses of these drugs helped improve outcomes in children and now we have found in young adults. Young adults include patients up to 40 years old and, in some circumstances, up to 50 or 55 years old. They can tolerate these intensive diets and we see better results, so better survival and fewer relapses. We have incorporated these types of treatment regimens into the treatment of younger patients with acute lymphoblastic leukemia.

]]>
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sean Maduck Sells 25,000 Shares http://www.sbs-internetsolutions.com/corcept-therapeutics-incorporated-nasdaqcort-insider-sean-maduck-sells-25000-shares/ Tue, 15 Nov 2022 23:47:03 +0000 http://www.sbs-internetsolutions.com/corcept-therapeutics-incorporated-nasdaqcort-insider-sean-maduck-sells-25000-shares/ Insider Sean Maduck of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) sold 25,000 shares of the company in a trade on Thursday, November 10. The shares were sold at an average price of $25.57, for a total transaction of $639,250.00. Following the transaction, the insider now directly owns 56,462 shares of the company, valued at […]]]>

Insider Sean Maduck of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) sold 25,000 shares of the company in a trade on Thursday, November 10. The shares were sold at an average price of $25.57, for a total transaction of $639,250.00. Following the transaction, the insider now directly owns 56,462 shares of the company, valued at $1,443,733.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link.

Sean Maduck also recently made the following trade(s):

  • On Monday, October 3, Sean Maduck sold 25,000 shares of Corcept Therapeutics. The shares were sold at an average price of $25.64, for a total transaction of $641,000.00.

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics rose $0.87 on Tuesday, hitting $26.69. The company had a trading volume of 560,203 shares, compared to an average volume of 772,679. The company has a market capitalization of $2.87 billion, a price/earnings ratio of 26.77, a P/E ratio /G of 2.56 and a beta of 0.56. The company’s 50-day moving average price is $26.58 and its two-hundred-day moving average price is $25.02. Corcept Therapeutics Incorporated has a 1 year minimum of $15.82 and a 1 year maximum of $30.14.

A Wall Street analyst gives his opinion

A number of equity research analysts have recently commented on CORT shares. StockNews.com downgraded Corcept Therapeutics from a “strong buy” rating to a “buy” rating in a research report on Saturday. Truist Financial downgraded shares of Corcept Therapeutics to a “hold” rating in a Tuesday, August 9 report. Jefferies Financial Group upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and raised its price target for the stock from $21.00 to $35.00 in a research report from the Wednesday, July 27. Finally, HC Wainwright raised its price target on Corcept Therapeutics shares from $29.00 to $33.00 and gave the company a “buy” rating in a Thursday, Aug. 4 research report. One investment analyst gave the stock a hold rating and four gave the company’s stock a buy rating. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional entries and exits

Institutional investors and hedge funds have recently been buying and selling shares of the company. Gladius Capital Management LP purchased a new stake in shares of Corcept Therapeutics in Q2 worth approximately $31,000. Quadrant Capital Group LLC increased its stake in Corcept Therapeutics by 714.0% during the third quarter. Quadrant Capital Group LLC now owns 1,571 shares of the biotech company valued at $40,000 after buying 1,378 additional shares in the last quarter. Financial Management Professionals Inc. acquired a new stake in Corcept Therapeutics in Q2 worth approximately $47,000. Altshuler Shaham Ltd increased its stake in Corcept Therapeutics by 67.6% in the third quarter. Altshuler Shaham Ltd now owns 2,286 shares of the biotech company worth $58,000 after buying 922 more shares in the last quarter. Finally, Lazard Asset Management LLC increased its position in Corcept Therapeutics shares by 2,286.8% during the second quarter. Lazard Asset Management LLC now owns 2,530 shares of the biotech company valued at $60,000 after purchasing an additional 2,424 shares during the period. 78.46% of the shares are held by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

(Get an assessment)

Corcept Therapeutics Incorporated discovers, develops and markets drugs for the treatment of serious metabolic, oncological and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not candidates for surgery.

Featured articles

Insider buying and selling by quarter for Corcept Therapeutics (NASDAQ:CORT)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Corcept Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Corcept Therapeutics wasn’t on the list.

Although Corcept Therapeutics currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Teledyne Technologies Incorporated (NYSE:TDY) Brief Update on Interests http://www.sbs-internetsolutions.com/teledyne-technologies-incorporated-nysetdy-brief-update-on-interests/ Sat, 12 Nov 2022 08:38:59 +0000 http://www.sbs-internetsolutions.com/teledyne-technologies-incorporated-nysetdy-brief-update-on-interests/ Teledyne Technologies Incorporated (NYSE:TDY – Get Rating) experienced a significant drop in short-term interest during the month of October. As of October 31, there was short interest totaling 780,300 shares, down 20.5% from the total of 982,100 shares as of October 15. Based on an average daily trading volume of 269,000 shares, the short-term interest […]]]>

Teledyne Technologies Incorporated (NYSE:TDY – Get Rating) experienced a significant drop in short-term interest during the month of October. As of October 31, there was short interest totaling 780,300 shares, down 20.5% from the total of 982,100 shares as of October 15. Based on an average daily trading volume of 269,000 shares, the short-term interest rate ratio is currently 2.9 days. Approximately 1.7% of the company’s shares are sold short.

Insiders place their bets

Separately, Vice President Cynthia Y. Belak sold 5,046 shares of the company in a transaction dated Tuesday, November 8. The stock was sold at an average price of $412.05, for a total transaction of $2,079,204.30. Following the completion of the transaction, the vice president now owns 4,457 shares of the company, valued at approximately $1,836,506.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Separately, director Michael T. Smith sold 4,000 shares of the company in a transaction dated Thursday, November 10. The stock was sold at an average price of $419.49, for a total transaction of $1,677,960.00. Following the transaction, the administrator now directly owns 56,073 shares of the company, valued at $23,522,062.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Additionally, Vice President Cynthia Y. Belak sold 5,046 shares of the company in a transaction dated Tuesday, November 8. The shares were sold at an average price of $412.05, for a total value of $2,079,204.30. Following the transaction, the vice president now owns 4,457 shares of the company, valued at $1,836,506.85. The disclosure of this sale can be found here. Insiders hold 2.60% of the shares of the company.

Institutional investors weigh in on Teledyne Technologies

A number of large investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its position in Teledyne Technologies by 11.3% during the third quarter. Envestnet Asset Management Inc. now owns 61,464 shares of the scientific and technical instruments company worth $20,742,000 after acquiring an additional 6,251 shares in the last quarter. King Luther Capital Management Corp increased its position in Teledyne Technologies by 4.2% during the third quarter. King Luther Capital Management Corp now owns 482,953 shares of the scientific and technical instruments company worth $162,982,000 after acquiring 19,651 additional shares in the last quarter. Nomura Asset Management Co. Ltd. increased its position in Teledyne Technologies by 4.9% in the third quarter. Nomura Asset Management Co. Ltd. now owns 10,856 shares of the scientific and technical instruments company worth $3,664,000 after acquiring 508 additional shares in the last quarter. Quadrant Capital Group LLC increased its position in Teledyne Technologies by 11.3% during the third quarter. Quadrant Capital Group LLC now owns 325 shares of the scientific and technical instruments company worth $110,000 after acquiring 33 additional shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Teledyne Technologies by 10.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 278,729 shares of the scientific and engineering instruments company worth $94,083,000 after acquiring an additional 27,012 shares in the last quarter. 89.77% of the shares are currently held by institutional investors.

A Wall Street analyst gives his opinion

Several stock analysts have recently released reports on the company. StockNews.com picked up coverage from Teledyne Technologies in a Wednesday, October 12 research note. They have set a “holding” rating on the stock. TheStreet upgraded Teledyne Technologies from a “c+” rating to a “b-” rating in a Friday, August 5 research note. Morgan Stanley lowered its price target on Teledyne Technologies from $470.00 to $445.00 and set an “underweight” rating on the stock in a Tuesday, August 16 research note. Finally, Needham & Company LLC lowered its price target on Teledyne Technologies from $520.00 to $472.00 and set a “buy” rating on the stock in a Thursday, July 28 research note.

Teledyne Technologies down 2.0%

TDY stock opened at $412.99 on Friday. Teledyne Technologies has a 1 year low of $325.00 and a 1 year high of $493.97. The company has a market capitalization of $19.36 billion, a P/E ratio of 27.21, a P/E/G ratio of 3.20 and a beta of 1.10. The company’s 50-day moving average is $367.37 and its 200-day moving average is $383.08. The company has a current ratio of 1.78, a quick ratio of 1.19 and a debt ratio of 0.47.

About Teledyne Technologies

(Get a rating)

Teledyne Technologies Incorporated provides enabling technologies for industrial growth markets in the United States, Canada, United Kingdom, Belgium, Netherlands and internationally. The Company’s Instrumentation segment offers monitoring and control instruments for marine, environmental, industrial and other applications, as well as electronic test and measurement equipment; and power and communication connectivity devices for distributed instrumentation systems and sensor networks.

See also

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Teledyne Technologies, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Teledyne Technologies was not on the list.

While Teledyne Technologies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Wireless POS Terminal Market: Key Market Players Aures Group, Diebold Nixdorf, Incorporated. http://www.sbs-internetsolutions.com/wireless-pos-terminal-market-key-market-players-aures-group-diebold-nixdorf-incorporated/ Wed, 09 Nov 2022 14:28:00 +0000 http://www.sbs-internetsolutions.com/wireless-pos-terminal-market-key-market-players-aures-group-diebold-nixdorf-incorporated/ Wireless Point of Sale Terminal Market Wireless POS Terminal Market: Key Market Players Aures Group, Diebold Nixdorf, Incorporated. PORTLAND, OR, USA, Nov. 9, 2022 /EINPresswire.com/ — According to the report published by Allied Market Research, the global wireless POS terminal market earned $7.9 billion in 2021 and is expected to generate $24.8 billion by 2031, […]]]>

Wireless Point of Sale Terminal Market

Wireless POS Terminal Market: Key Market Players Aures Group, Diebold Nixdorf, Incorporated.

PORTLAND, OR, USA, Nov. 9, 2022 /EINPresswire.com/ — According to the report published by Allied Market Research, the global wireless POS terminal market earned $7.9 billion in 2021 and is expected to generate $24.8 billion by 2031, growing at a CAGR of 12.5% ​​from 2022 to 2031. The report provides in-depth analysis of changing market dynamics, major segments, value chain , the competitive scenario and the regional landscape. This research offers valuable guidance for key players, investors, shareholders, and startups to design sustainable growth strategies and gain competitive advantage in the market.

Technological advancements in wireless POS terminals, such as the inclusion of machine learning (ML) and automation, provide potential opportunities for the expansion of the global wireless POS terminal market . Additionally, the growth of wireless POS terminal systems during the pandemic has enabled the interaction of customer relationship management (CRM) along with other financial solutions for organizations. Based on region, Asia Pacific held the largest share in 2021.

Download Free Sample Report (Get Detailed Analysis in PDF Format – 408+ Pages): https://www.alliedmarketresearch.com/request-sample/15055

The research provides detailed segmentation of the global Wireless POS Terminal market on the basis of component, type, application, industry vertical, and region. The report discusses the segments and their sub-segments in detail with the help of tables and figures. Market players and investors can strategize based on the most revenue-generating and fastest-growing segments mentioned in the report.

Based on components, the hardware segment held the highest share in 2021, accounting for more than half of the global wireless POS terminal market, and is expected to maintain its leading status during the forecast period. . However, the software segment is expected to register the highest CAGR of 15.3% from 2022 to 2031.

Based on applications, the front-end segment accounted for the highest share in 2021, contributing nearly three-quarters of the global wireless POS terminal market, and is expected to maintain its revenue lead during the period. forecast. However, the back-end segment is expected to show the highest CAGR of 14.6% from 2022 to 2031.

Based on the industry vertical, the retail segment accounted for the highest share in 2021, holding approximately two-fifths of the global wireless POS terminal market, and is expected to maintain its status as the leader during the forecast period. However, the transportation segment is expected to grow at the highest CAGR of 18.4% during the forecast period.

Based on region, Asia-Pacific held the largest share in 2021, contributing more than one-third of the total wireless POS terminal market share, and is expected to maintain its dominant share in terms of revenue in 2031. Furthermore, the same region is expected to show the fastest CAGR of 15.4% during the forecast period. The research also analyzes regions such as North America, Europe and LAMEA.

Key players in the global Wireless POS Terminal market analyzed in the research include Aures Group, Diebold Nixdorf, Incorporated, Hewlett Packard Enterprise Development LP.

The report provides a detailed analysis of these key players in the global Wireless Point of Sale Terminals market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements and others to increase their market share and maintain dominant shares in different regions. The report is valuable for highlighting the business performance, operating segments, product portfolio, and strategic moves of market players to present the competitive scenario.

MAIN BENEFITS FOR STAKEHOLDERS

This report provides a quantitative analysis of market segments, current trends, estimates and forecast dynamics of the Wireless POS Terminals market from 2021 to 2031 to identify the POS Terminals market opportunities. wireless sale.
In addition to market research, important drivers, restraints and opportunities are also covered.
Porter’s Five Forces analysis highlights the ability of buyers and suppliers to enable stakeholders to make profit-driven business decisions and strengthen their supplier-buyer network.
In-depth analysis of Wireless POS Terminal market segmentation helps to determine the existing market opportunities.
Based on their contribution to global market revenue, major countries in each region are mapped.
The positioning of market players facilitates benchmarking and provides a clear understanding of the current position of market players.
The report includes analysis of regional and global Wireless POS Terminal market trends, key players, market segments, application areas and market growth strategies.

Type

Portable counter and PIN pad
mPOS
Smart POS
Others
Application

Front end
Back End
industry vertical

Detail
Hospitality
Hospitality
Full Service Restaurant (FSR)
Quick Service Restaurant (QSR)
Institutional RSF
Others
Health care
Entertainment
Transportation
Others
By region:

North America (USA, Canada)
Europe (UK, Germany, France, Italy, Spain, Netherlands, Rest of Europe)
Asia Pacific (China, Japan, India, Australia, South Korea, Singapore, Rest of Asia Pacific)
LAMEA (Latin America, Middle East, Africa)

Buy now: https://bit.ly/3UcToOm

Related reports:

Payday Loans Market: https://www.alliedmarketresearch.com/payday-loans-market-A10012

Open Banking Market: https://www.alliedmarketresearch.com/open-banking-market

Online Banking Market: https://www.alliedmarketresearch.com/online-banking-market

Florida Digital Lending Market: https://www.alliedmarketresearch.com/florida-digital-lending-market-A11092

mayuri
Allied Market Research
+1 8007925285
write to us here

]]>
MCSO to incorporate additional security measures following sexual assaults on the Riverwalk http://www.sbs-internetsolutions.com/mcso-to-incorporate-additional-security-measures-following-sexual-assaults-on-the-riverwalk/ Sun, 06 Nov 2022 15:18:35 +0000 http://www.sbs-internetsolutions.com/mcso-to-incorporate-additional-security-measures-following-sexual-assaults-on-the-riverwalk/ COLUMBUS, Ga. (WRBL)— The Muscogee County Sheriff’s Office is working to make the Riverwalk a safer place. Sheriff Greg Countryman took to Facebook to share the addition of two full-time bike deputies who will be dedicated to patrolling the Riverwalk and select parks. He cites the new role for several recent incidents involving sexual assault […]]]>

COLUMBUS, Ga. (WRBL)— The Muscogee County Sheriff’s Office is working to make the Riverwalk a safer place.

Sheriff Greg Countryman took to Facebook to share the addition of two full-time bike deputies who will be dedicated to patrolling the Riverwalk and select parks.

He cites the new role for several recent incidents involving sexual assault and sexual harassment on the Riverwalk.

“We had, I know three women, sexually assaulted on our Riverwalk. As sheriff, I don’t want that to happen again,” Countryman said.

One of the most recent incidents on the Riverwalk occurred last July when a man exposed himself to individuals on the Riverwalk while performing a lewd act.

Several other victims reported similar experiences, with one victim taking a photo of the suspect, whom Columbus police later identified as 28-year-old Javion Howard.

Howard was arrested and charged with four counts of indecent exposure.

Countryman says its goal is to eliminate such incidents and ensure the citizens of Columbus, especially women and children, feel safe using our county’s great amenities.

Sheriff Countryman’s full message is below.

]]>
Dana Incorporated expects quarterly dividend of $0.10 (NYSE: DAN) http://www.sbs-internetsolutions.com/dana-incorporated-expects-quarterly-dividend-of-0-10-nyse-dan/ Fri, 28 Oct 2022 15:19:41 +0000 http://www.sbs-internetsolutions.com/dana-incorporated-expects-quarterly-dividend-of-0-10-nyse-dan/ Dana Incorporated (NYSE:DAN – Get Rating) announced a quarterly dividend on Wednesday, October 26, Zacks reports. Shareholders of record on Friday, November 11 will receive a dividend of 0.10 per share from the auto parts company on Friday, December 2. This represents an annualized dividend of $0.40 and a dividend yield of 2.59%. The ex-date […]]]>

Dana Incorporated (NYSE:DAN – Get Rating) announced a quarterly dividend on Wednesday, October 26, Zacks reports. Shareholders of record on Friday, November 11 will receive a dividend of 0.10 per share from the auto parts company on Friday, December 2. This represents an annualized dividend of $0.40 and a dividend yield of 2.59%. The ex-date of this dividend is Wednesday, November 9.

Dana has a payout ratio of 22.0%, which means that its dividend is sufficiently covered by earnings. Analysts expect Dana to earn $1.76 per share next year, meaning the company should continue to be able to cover its $0.40 annual dividend with an expected future payout ratio. by 22.7%.

Dana’s price performance

DAN lost $0.59 during Friday’s trading, hitting $15.44. The stock recorded trading volume of 48,325 shares, compared to an average trading volume of 1,438,724 shares. Dana has a 1-year low of $11.17 and a 1-year high of $25.51. The company has a market capitalization of $2.21 billion, a price-earnings ratio of 22.78 and a beta of 2.27. The stock has a 50-day moving average of $13.94 and a two-hundred-day moving average of $14.97. The company has a quick ratio of 0.91, a current ratio of 1.52 and a debt ratio of 1.24.

Dana (NYSE:DAN – Get Rating) last reported quarterly earnings data on Wednesday, August 3. The auto parts company reported EPS of $0.08 for the quarter, missing analyst consensus estimates of $0.21 per ($0.13). Dana had a return on equity of 4.89% and a net margin of 1.03%. The company posted revenue of $2.59 billion for the quarter, versus analyst estimates of $2.45 billion. In the same quarter a year earlier, the company posted earnings of $0.59 per share. The company’s revenue increased by 17.3% compared to the same quarter last year. As a group, equity analysts expect Dana to post 0.68 EPS for the current fiscal year.

Institutional investors weigh in on Dana

A number of hedge funds have recently changed their holdings in the company. Gamco Investors Inc. ET AL increased its stake in Dana by 9.6% during the 1st quarter. Gamco Investors Inc. ET AL now owns 3,612,318 shares of the auto parts company worth $63,468,000 after purchasing an additional 316,466 shares in the last quarter. Gabelli Funds LLC increased its position in Dana shares by 2.3% in the first quarter. Gabelli Funds LLC now owns 2,621,679 shares of the auto parts company worth $46,063,000 after buying an additional 60,025 shares in the last quarter. Rhumbline Advisers increased its holdings in Dana by 1.5% in the first quarter. Rhumbline Advisers now owns 427,547 shares of the auto parts company worth $7,512,000 after buying an additional 6,465 shares in the last quarter. MetLife Investment Management LLC increased its position in Dana by 41.1% in the first quarter. MetLife Investment Management LLC now owns 169,160 shares of the auto parts company valued at $2,972,000 after buying an additional 49,268 shares last quarter. Finally, Yousif Capital Management LLC increased its stake in Dana by 2.9% in the 1st quarter. Yousif Capital Management LLC now owns 82,651 shares of the auto parts company valued at $1,452,000 after buying 2,303 additional shares in the last quarter. Institutional investors and hedge funds own 95.98% of the company’s shares.

Changes to analyst ratings

DAN has been the subject of several analyst reports. Royal Bank of Canada downgraded Dana’s shares from an “outperform” rating to an “sector performance” rating and raised its price target for the stock from $15.00 to $16.00 in a research note Friday. Wells Fargo & Company raised its price target on Dana from $15.00 to $16.00 and gave the stock an “equal weight” rating in a Thursday, Aug. 4, report. StockNews.com began covering Dana in a report on Wednesday, October 12. They set a “hold” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded Dana’s shares from a “buy” rating to a “hold” rating and reduced its price target for the stock from $18.00 to $15.00 in a report of research from Thursday August 4th. Seven analysts rated the stock with a holding rating. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $15.75.

About Dana

(Get a rating)

Dana Incorporated provides energy transportation and energy management solutions for vehicles and machinery in North America, Europe, South America and Asia-Pacific. It operates in four segments: Light Vehicle Drive Systems, Commercial Vehicle Drive & Motion Systems, Off-Road Drive & Motion Systems and Power Technologies.

Further reading

Dividend history for Dana (NYSE:DAN)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Dana, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Dana wasn’t on the list.

Although Dana currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Is Bentley Systems, Incorporated’s (NASDAQ:BSY) ROE of 21% impressive? http://www.sbs-internetsolutions.com/is-bentley-systems-incorporateds-nasdaqbsy-roe-of-21-impressive/ Tue, 25 Oct 2022 15:19:45 +0000 http://www.sbs-internetsolutions.com/is-bentley-systems-incorporateds-nasdaqbsy-roe-of-21-impressive/ While some investors are already familiar with financial metrics (hat trick), this article is for those who want to learn more about return on equity (ROE) and why it matters. To keep the lesson grounded in practicality, we’ll use ROE to better understand Bentley Systems, Incorporated (NASDAQ:BSY). ROE or return on equity is a useful […]]]>

While some investors are already familiar with financial metrics (hat trick), this article is for those who want to learn more about return on equity (ROE) and why it matters. To keep the lesson grounded in practicality, we’ll use ROE to better understand Bentley Systems, Incorporated (NASDAQ:BSY).

ROE or return on equity is a useful tool for evaluating how effectively a company can generate returns on the investment it has received from its shareholders. In short, ROE shows the profit that each dollar generates in relation to the investments of its shareholders.

Our analysis indicates that BSY is potentially undervalued!

How is ROE calculated?

The ROE formula is:

Return on equity = Net income (from continuing operations) ÷ Equity

So, based on the formula above, the ROE for Bentley Systems is:

21% = $103 million ÷ $497 million (based on trailing 12 months to June 2022).

“Yield” refers to a company’s earnings over the past year. This means that for every dollar of shareholders’ equity, the company generated $0.21 in profit.

Does Bentley Systems have a good ROE?

A simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, as companies differ quite a bit within the same industry classification. Fortunately, Bentley Systems has an ROE above the software industry average (13%).

NasdaqGS:BSY Return on Equity October 25, 2022

It’s a good sign. However, keep in mind that a high ROE does not necessarily indicate efficient profit generation. Especially when a company uses high levels of debt to finance its debt, which can increase its ROE, but the high leverage puts the company at risk. To learn about the 3 risks we have identified for Bentley Systems, visit our free Risk Dashboard.

Why You Should Consider Debt When Looking at ROE

Virtually all businesses need money to invest in the business, to increase their profits. The money for the investment can come from the previous year’s earnings (retained earnings), from issuing new shares or from borrowing. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, debt used for growth will enhance returns, but will not affect total equity. So using debt can improve ROE, but with the added risk of stormy weather, metaphorically speaking.

Combine Bentley Systems debt and its 21% return on equity

It appears that Bentley Systems is using a huge volume of debt to finance the company, as it has an extremely high debt-to-equity ratio of 3.68. Its ROE is respectable, but it’s not that impressive once you consider all of the debt.

Conclusion

Return on equity is a way to compare the business quality of different companies. Companies that can earn high returns on equity without too much debt are generally of good quality. If two companies have roughly the same level of debt and one has a higher ROE, I generally prefer the one with a higher ROE.

But when a company is of high quality, the market often gives it a price that reflects that. Earnings growth rates, relative to expectations reflected in the share price, are particularly important to consider. You might want to take a look at this data-rich interactive chart of the company’s forecast.

Sure Bentley Systems may not be the best stock to buy. So you might want to see this free collection of other companies that have high ROE and low debt.

Valuation is complex, but we help make it simple.

Find out if Bentley Systems is potentially overvalued or undervalued by viewing our full analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.

See the free analysis

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

]]>
Hamilton Lane Incorporated is expected to earn $0.63 per share in the second quarter of 2023. (NASDAQ: HLNE) http://www.sbs-internetsolutions.com/hamilton-lane-incorporated-is-expected-to-earn-0-63-per-share-in-the-second-quarter-of-2023-nasdaq-hlne/ Fri, 21 Oct 2022 21:56:46 +0000 http://www.sbs-internetsolutions.com/hamilton-lane-incorporated-is-expected-to-earn-0-63-per-share-in-the-second-quarter-of-2023-nasdaq-hlne/ Shares of Hamilton Lane, Inc. may be identified on NASDAQ by the symbol HLNE. In a research report published on Tuesday, October 18, Oppenheimer lowered its earnings per share (EPS) expectation for Hamilton Lane for the second quarter of 2023. The report was distributed worldwide. Oppenheimer analyst C. Kotowski predicted the company would earn $0.63 […]]]>

Shares of Hamilton Lane, Inc. may be identified on NASDAQ by the symbol HLNE. In a research report published on Tuesday, October 18, Oppenheimer lowered its earnings per share (EPS) expectation for Hamilton Lane for the second quarter of 2023. The report was distributed worldwide. Oppenheimer analyst C. Kotowski predicted the company would earn $0.63 per share for the quarter. That’s down from the previous estimate, which was $0.73 per share. Hamilton Lane is expected to generate earnings of $3.14 per share for the full fiscal year. Oppenheimer also predicts that Hamilton Lane will earn $0.74 per share in Q3 2023, $0.83 per share in Q4 2023, $3.12 per share in fiscal 2023, $0.85 per share in first quarter 2024, $0.90 per share in the second. quarter of 2024, $0.94 per share in the third quarter of 2024 and $0.95 per share in the fourth quarter of 2024, as well as $3.64 per share in fiscal 2024.
Additionally, HLNE has been discussed in a wide variety of other reports that have been published. Following the release of research on Wednesday, UBS Group lowered both its “neutral” rating for Hamilton Lane, which it had previously assigned, and its price target for the company, which it had set at 75 dollars but which it has now lowered to 68 dollars, respectively. . The target price for Hamilton Lane has been reduced by $2 from $74.00 to $72.00, according to a report released by Wells Fargo & Company on Wednesday, July 13. The company’s shares were also given an “equal weight” rating. which indicates that the value of each share is equivalent. In a research report released Wednesday, Morgan Stanley lowered its “equal weight” rating on Hamilton Lane shares and its price target on those shares, which had previously been set at $72.00. The new target price is $67.00. In a research note released June 29, Goldman Sachs Group lowered its price target on Hamilton Lane shares from $85.00 to $76.00 and assigned the company a “neutral” rating. This was the latest news regarding the company’s financial performance.
On Thursday, the price of a Hamilton Lane share was $59.19 when trading first opened. The simple moving average of the company’s stock price over the past 50 days is $67.97 and the average for the past 200 days is $68.90. The debt ratio is calculated at 0.45, the current ratio is calculated at 1.86 and the quick ratio is also calculated at 1.86. Over the previous twelve months, property prices on Hamilton Lane ranged from a low of $55.81 to a high of $116.00. The company’s price/earnings ratio is 14.40 and its beta value is 1.02 at the moment. The company’s total value, measured by its market capitalization, is $3.15 billion.

On August 2, investors had access to the latest earnings report from Hamilton Lane, a NASDAQ-listed company under the symbol HLNE. The company’s earnings per share for the quarter came in at $0.92, $0.12 above the consensus estimate by industry professionals of $0.80. The company’s return on equity was calculated at 52.70% and the company’s net margin was calculated at 42.33%. Revenue for the quarter was well above the $100.20 million forecast by analysts, coming in instead at $135.51 million.

Additionally, the company just announced and paid a quarterly dividend, which was done on Thursday, October 6th. On September 15, a dividend payment of $0.40 was made to shareholders of record upon declaration of the dividend. Calculated annually, this equates to a dividend payment of $1.60 per year and a yield of 2.70%. The ex-dividend date of this dividend was September 14 and this day also marked the start of the payment period. The payment period will last until the next ex-dividend date. Currently, the dividend payout ratio for Hamilton Lane is 38.93%.

Recent stock purchases and sales have involved the participation of various institutional investors, including hedge funds, among other types of investment vehicles. The company made a new investment in Hamilton Lane during the first quarter of the year, resulting in a total expenditure of $61,309,000. The percentage of Hamilton Lane, owned by Wellington Management Group LLP, increased by 13.8% in the first three months of 2018. Due to the purchase of an additional 498,381 shares of the company during the previous quarter, Wellington Management Group LLP now holds 4,119,730 shares. the shares of the company, which have a value of $318,414,000. Wellington Management Group LLP purchased these shares. During the second quarter, TimesSquare Capital Management LLC achieved a 65.8% increase in the proportion of shares of Hamilton Lane it held. Following the purchase of an additional 311,610 shares during the last quarter, TimesSquare Capital Management LLC now owns a total of 785,510 shares of the company, worth $52,771,000. This brings the total number of shares held by the company to 785,510. Clearbridge Investments LLC increased its stake in Hamilton Lane by 24.3% during the second quarter by purchasing additional shares of the company. Following the purchase of an additional 209,377 shares during the last quarter, Clearbridge Investments LLC now owns 1,071,630 shares of the company, valued at $71,992,000. This brings the total number of shares held by the company to 1,071,630. Finally, during the second quarter, Citadel Advisors LLC expanded its investment portfolio by purchasing an additional 53.3% of shares in Hamilton Lane. Following the acquisition of 167,945 shares during the last quarter, Citadel Advisors LLC now owns 483,189 shares of the company. The current market value of these shares is $32,460,000. Institutional investors and hedge funds own 64.80% of the company’s total number of shares.

]]>
Quest Diagnostics Incorporated (NYSE:DGX) sees sharp drop in short-term interest http://www.sbs-internetsolutions.com/quest-diagnostics-incorporated-nysedgx-sees-sharp-drop-in-short-term-interest/ Tue, 18 Oct 2022 20:01:31 +0000 http://www.sbs-internetsolutions.com/quest-diagnostics-incorporated-nysedgx-sees-sharp-drop-in-short-term-interest/ Quest Diagnostics Incorporated (NYSE:DGX – Get Rating) was the target of a sharp drop in short-term interest in September. As of September 30, there was short interest totaling 5,220,000 shares, down 5.6% from the September 15 total of 5,530,000 shares. Based on an average daily trading volume of 853,300 shares, the short-term interest rate ratio […]]]>

Quest Diagnostics Incorporated (NYSE:DGX – Get Rating) was the target of a sharp drop in short-term interest in September. As of September 30, there was short interest totaling 5,220,000 shares, down 5.6% from the September 15 total of 5,530,000 shares. Based on an average daily trading volume of 853,300 shares, the short-term interest rate ratio is currently 6.1 days. Currently, 4.5% of the company’s shares are sold short.

Analysts set new price targets

A number of research companies have recently commented on DGX. Morgan Stanley reaffirmed an “equal weight” rating and issued a price target of $142.00 on Quest Diagnostics shares in a Monday, August 22 report. StockNews.com began covering Quest Diagnostics in a research report on Wednesday, October 12. They set a “buy” rating for the company. Six research analysts rated the stock with a hold rating and three gave the company a buy rating. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $148.50.

Quest Diagnostics trading up 1.3%

DGX traded $1.70 on Tuesday, hitting $129.63. The company had a trading volume of 32,667 shares, compared to an average volume of 903,014. The company has a market capitalization of $15.12 billion, a PE ratio of 10.64 and a beta of 0.96. The company has a quick ratio of 1.42, a current ratio of 1.54 and a debt ratio of 0.62. The company’s fifty-day simple moving average is $128.34 and its 200-day simple moving average is $133.34. Quest Diagnostics has a 12 month minimum of $120.40 and a 12 month maximum of $174.16.

Quest Diagnostics (NYSE:DGX – Get Rating) last released its quarterly results on Thursday, July 21. The medical research company reported EPS of $2.36 for the quarter, beating analyst consensus estimates of $2.26 by $0.10. Quest Diagnostics had a net margin of 14.02% and a return on equity of 24.62%. The company posted revenue of $2.45 billion in the quarter, compared to $2.34 billion expected by analysts. During the same period of the previous year, the company achieved EPS of $3.18. The company’s revenue for the quarter was down 3.8% from the same quarter last year. Equity research analysts expect Quest Diagnostics to post EPS of 9.67 for the current year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 19. Shareholders of record on Tuesday, October 4 will receive a dividend of $0.66 per share. This represents an annualized dividend of $2.64 and a dividend yield of 2.04%. The ex-dividend date is Monday, October 3. Quest Diagnostics’ dividend payout ratio is currently 21.96%.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, Director Timothy M. Ring sold 2,000 shares of Quest Diagnostics in a trade dated Monday, August 1. The stock was sold at an average price of $136.04, for a total transaction of $272,080.00. Following completion of the transaction, the administrator now owns 23,933 shares of the company, valued at approximately $3,255,845.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. 1.70% of the shares are currently held by insiders.

Hedge funds weigh on Quest Diagnostics

A number of large investors have recently bought and sold shares of DGX. Mystic Asset Management Inc. acquired a new position in Quest Diagnostics stock during the fourth quarter worth $25,000. Wagner Wealth Management LLC acquired a new stake in Quest Diagnostics in the second quarter worth $27,000. Sandy Cove Advisors LLC acquired a new stake in Quest Diagnostics in the first quarter valued at $28,000. Chilton Capital Management LLC purchased a new stake in Quest Diagnostics in the second quarter for $36,000. Finally, Win Advisors Inc. increased its stake in Quest Diagnostics by 44.1% in the second quarter. Win Advisors Inc. now owns 271 shares of the medical research company valued at $37,000 after buying 83 additional shares in the last quarter. Institutional investors hold 88.87% of the company’s shares.

About Quest Diagnostics

(Get a rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and service in the United States and around the world. The Company develops and provides diagnostic information services, such as routine testing, non-routine and advanced clinical testing, pathology testing and other diagnostic information services.

Featured Articles

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Quest Diagnostics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Quest Diagnostics wasn’t on the list.

Although Quest Diagnostics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>